References

The 2021 WHO classification of tumors of the central nervous system: a summary

10.1093/neuonc/noab106 · 2021 · External reference

FIGO staging of endometrial cancer: 2023

10.1002/ijgo.14923 · 2023 · External reference

Unresolved reference

External reference

Colon cancer screening methods: 2023 update

2023 · External reference

Liquid biopsy: a distinctive approach to the diagnosis and prognosis of cancer

10.1177/11769351221076062 · 2022 · External reference

Molecular testing in breast cancer

2024 · External reference

Prevalence of UV mutational signatures among cutaneous primary tumors

10.1001/jamanetworkopen.2022.3833 · 2022 · External reference

Unique genomic landscape of high-grade neuroendocrine cervical carcinoma: implications for rethinking current treatment paradigms

2020 · External reference

Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families

10.1186/s12885-019-5494-7 · 2019 · External reference

Delivering precision oncology to patients with cancer

10.1038/s41591-022-01717-2 · 2022 · External reference

Quantifying the expanding landscape of clinical actionability for patients with cancer

10.1158/2159-8290.cd-23-0467 · 2024 · External reference

Companion diagnostics: state of the art and new regulations

10.1177/11772719211047763 · 2021 · External reference

Unresolved reference

External reference

Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review)

10.3892/or.2023.8543 · 2023 · External reference

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

10.1038/s41591-023-02226-6 · 2023 · External reference

Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: an exploratory analysis from the predator study of metastatic colorectal cancer (mCRC) patients undergoing surgical resection

10.3390/ijms231911529 · 2022 · External reference

Circulating tumor DNA in the management of early-stage breast cancer

10.3390/cells12121573 · 2023 · External reference

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

10.1016/s1470-2045(22)00555-1 · 2022 · External reference

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance

10.1038/srep20913 · 2016 · External reference

Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study

10.1186/s12943-023-01878-9 · 2023 · External reference

Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review

10.2217/fon-2021-1040 · 2022 · External reference

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

10.1016/s1470-2045(22)00541-1 · 2022 · External reference

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group

10.1016/j.annonc.2022.05.520 · 2022 · External reference

Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples

10.1200/po.22.00261 · 2022 · External reference

Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC)

10.1200/jco.2023.41.16_suppl.9076 · 2023 · External reference

Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab

10.1002/1878-0261.13349 · 2023 · External reference

Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non-small cell lung cancer

10.1158/1078-0432.ccr-23-1578 · 2023 · External reference

Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors

10.1001/jamaoncol.2018.2297 · 2018 · External reference

Clonal hematopoiesis of indeterminate potential in patients with solid tumor malignancies

10.1158/0008-5472.can-22-0985 · 2022 · External reference

Tumor genomic testing for >4,000 men with metastatic castration-resistant prostate cancer in the phase III trial profound (Olaparib)

10.1158/1078-0432.ccr-21-3940 · 2022 · External reference

Method of tissue acquisition affects success of comprehensive genomic profiling in lung cancer

10.5858/arpa.2021-0313-oa · 2023 · External reference

Amplification of nucleic acids

2023 · External reference

Molecular testing in lung cancer

2024 · External reference

Genome and transcriptome analysis

2023 · External reference

Proceedings from the ASCO/college of american pathologists immune checkpoint inhibitor predictive biomarker summit

10.1200/po.22.00454 · 2022 · External reference